BRCA1/2 testing in newly diagnosed breast & ovarian cancer patients without prior genetic counselling: the DNA-BONus study

open access - European Journal of Human Genetics

In conclusion, we show that BRCA1/2 mutation testing is well accepted among patients with newly diagnosed breast or ovarian cancer. We further conclude that current clinical guidelines are sufficient to identify the majority of the BRCA1/2 mutation carriers among patients with breast cancer. Because of the high prevalence of pathogenic BRCA1/2 variants, we recommend that all patients with epithelial ovarian cancer are offered germline BRCA1/2 testing, irrespective of age or family history of cancer.